Drugs / MEDI8968
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01838499 | May 2013 → Oct 2014 | hidradenitis suppurativa | AstraZeneca | Terminated | Missed primary |
| Phase 2 | NCT01448850 | Nov 2011 → Feb 2014 | chronic obstructive pulmonary disease | MedImmune LLC | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI8968 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01448850 ↗ |
| Modality | Monoclonal antibody | “MEDI8968, a fully human monoclonal antibody” PMID 28793896 ↗ Aug 2017 |
| Route | Intravenous | “600 milligram (mg) as intravenous (IV) infusion” NCT01448850 ↗ |
| Target | IL1R1 | “MEDI8968, a fully human monoclonal antibody, binds selectively to IL-1R1” PMID 28793896 ↗ Aug 2017 |